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1. INTRODUCTION {#cam43192-sec-0005}
===============

In the United States (US), the human papillomavirus (HPV) causes about 33 700 cancers each year, including cancers of the cervix, vagina, vulva, oropharynx, and anus.[^1^](#cam43192-bib-0001){ref-type="ref"} Following approval by the Food and Drug Administration (FDA), the American Committee on Immunization Practices (ACIP) recommended HPV vaccination for women in 2007 and for men in 2011.[^2^](#cam43192-bib-0002){ref-type="ref"} Despite constant efforts to promote knowledge of and accessibility to HPV vaccine, uptake in the US remains suboptimal.

Parental approval plays a key role in receipt of HPV vaccines by minor children.[^3^](#cam43192-bib-0003){ref-type="ref"} When children become legally adults (≥18 years of age), however, they no longer need approval from their parents/guardians to get vaccinated. Until 2018, HPV vaccination was recommended for US adults who have not previously been adequately immunized, through age 21 for men and 26 for women.[^2^](#cam43192-bib-0002){ref-type="ref"}, [^4^](#cam43192-bib-0004){ref-type="ref"} Despite these guidelines, HPV vaccination coverage in eligible adults remains low in the US. In 2016, only 8.6% of women and 2.7% of men aged 19‐26 years who had not received HPV vaccination prior to age 19, reported having had at least one dose of HPV vaccine.[^5^](#cam43192-bib-0005){ref-type="ref"} This is a matter of concern, as 64% to 82% of incident HPV DNA detected in mid‐age US adults (25 to 60 years of age) who engage in new sexual partnerships is attributable to newly acquired infection.[^6^](#cam43192-bib-0006){ref-type="ref"}, [^7^](#cam43192-bib-0007){ref-type="ref"}

There is a strong body of evidence suggesting that HPV vaccine is safe and effective in preventing HPV infection and HPV‐related disease in both teenagers and older age groups.[^8^](#cam43192-bib-0008){ref-type="ref"}, [^9^](#cam43192-bib-0009){ref-type="ref"}, [^10^](#cam43192-bib-0010){ref-type="ref"} Based on these data, the FDA approved the expanded use of HPV vaccine in 2018 to include individuals 27 through 45 years.[^11^](#cam43192-bib-0011){ref-type="ref"} Considering the increasing incidence of HPV‐associated cancers in the US, particularly oropharyngeal and anal cancers for which population‐based screening is not endorsed,[^12^](#cam43192-bib-0012){ref-type="ref"} the ACIP recently recommended HPV vaccination in this age group as part of the shared decision‐making process between patients and clinicians.[^13^](#cam43192-bib-0013){ref-type="ref"} This provides additional opportunities to people who did not receive the vaccine as minors, to benefit from it later in their life. In contrast to the compelling literature examining parents' reasons for not consenting their children to receive HPV vaccination,[^14^](#cam43192-bib-0014){ref-type="ref"} little is known about the reasons why eligible, independent adults still do not get the HPV vaccine.

In the state of Texas, the second most populated region of the US, the proportion of parents/guardians who exempt their children from vaccination for nonmedical reasons has risen over the last decade,[^15^](#cam43192-bib-0015){ref-type="ref"} to the point where public health officials anticipate resurging outbreaks of certain preventable diseases among vulnerable populations.[^16^](#cam43192-bib-0016){ref-type="ref"}, [^17^](#cam43192-bib-0017){ref-type="ref"} With only 43.5% of adolescents were being up‐to‐date on their HPV vaccine series in 2018, Texas is lagging behind most US states on HPV vaccination.[^18^](#cam43192-bib-0018){ref-type="ref"} The rates are even lower among vaccine‐eligible adults.[^8^](#cam43192-bib-0008){ref-type="ref"} However, factors that contribute to the suboptimal HPV vaccine uptake in this group have not been previously assessed from an individual\'s perspective. In this study, we examined: (i) the proportion and characteristics of vaccine‐eligible adults in Texas who have never received HPV vaccine; and (ii) their reasons for not getting vaccinated. Understanding these motivations may help identify effective interventions to improve HPV vaccine coverage in this population.

2. METHODS {#cam43192-sec-0006}
==========

2.1. Study population and recruitment procedure {#cam43192-sec-0007}
-----------------------------------------------

Our study population was selected from a representative sample of the Texas population; the enrolment procedure has been described in detail elsewhere.[^19^](#cam43192-bib-0019){ref-type="ref"}, [^20^](#cam43192-bib-0020){ref-type="ref"} Briefly, a nonprobability sample of 2050 respondents to the Texas health screening survey was collected between 5 February and 5 March 2018, using strata set to mirror Texas demographics for sex, ethnicity, race, and income. However, oversampling of non‐Hispanic Blacks (NHBs) was conducted to ensure more accurate estimation in this minority group. The non‐Hispanic White (NHW) category consisted of those selecting White as the sole race and the NHB category as those selecting Black/African American (either alone or in addition to other races). The recruitment target included 60% urban and 40% rural respondents, categorized by matching ZIP code to county designations.[^21^](#cam43192-bib-0021){ref-type="ref"}, [^22^](#cam43192-bib-0022){ref-type="ref"} The instrument was prepared in English with Mexican Spanish translation with the help of Masterword Services, Inc, Houston, TX, and loaded into the Qualtrics online survey platform. Qualtrics managed hosting and compensation of the survey using opt‐in panelists. The study protocol (PA16‐0724) was approved by MD Anderson\'s Institutional Review Board. The present study focused on the population of adult respondents who were eligible for HPV vaccination, that is, women participants who were aged ≤ 26 years, and men participants who were aged ≤ 21 years when HPV vaccination was first recommended in the US (ie in 2007 for women and 2011 for men). Thus, our study sample consisted of 907 respondents, including 724 women aged ≤ 26 years in 2007 (≤38 years at the time of survey), and 183 men aged ≤ 21 years in 2011 (≤28 years at the time of survey).

2.2. Outcome measures {#cam43192-sec-0008}
---------------------

The main outcomes for this study were: (a) self‐reported receipt of HPV vaccine, and (b) self‐reported reasons for not receiving HPV vaccine. To measure these outcomes, we adapted two validated questions from the National Immunization Survey‐Teen (NIS‐Teen). In the Texas health screening survey, these questions were directed to adult respondents who were or have been eligible to receive HPV vaccination. We first asked: (a) *HPV is a common sexually transmitted virus that can cause genital warts and cervical and other types of cancer in men and women. Vaccines to prevent some HPV infections are available for men and women 9 ‐ 26 years of age and are sometimes called the HPV shot, Cervarix, or Gardasil. Have you ever received the HPV shot, Cervarix, or Gardasil?* The possible responses were: *Yes/No/Don\'t know*. Participants who responded "No" were asked: (b) *What is the main reason you have not received the HPV shot/ vaccine?* Possible responses were: *Provider did not recommend (a), Did not know about the vaccine (b), Vaccine not needed or necessary (c), Not required to get the vaccine (d), Safety concerns (e), Provider indicated could vaccinate later (f), Uninsured or insurance doesn\'t fully cover shots, or co‐pay or other costs too high (g), Shot could be painful (h), Vaccine not available (i), Difficulty making or getting to appointments/ transportation issues (j), Concern about increasing sexual activity if receive shot (k), Not sexually active (l), Some other reason (m)*.

2.3. Covariates {#cam43192-sec-0009}
---------------

Covariates were selected based on their potential influence on HPV vaccination uptake, including: socio‐demographic factors of age, ethnicity/race, nativity, educational attainment, marital status, occupation, rurality, and household income; behavioral and mental factors; and health‐related variables such as smoking status, health coverage, vaccination against Hepatitis B virus (HBV), hormonal contraception use, and family history of any cancer.

2.4. Statistical analysis {#cam43192-sec-0010}
-------------------------

Data were weighted by ICF International, Inc, Fairfax, Virginia using a three‐dimensional raking approach with iterative post‐stratification based on sex, age, and race/ethnicity.[^23^](#cam43192-bib-0023){ref-type="ref"} We used means and standard deviation (continuous variables), weighted percentages and weighted 95% confidence interval (categorical variables), to describe the study population by HPV vaccination status. The reasons for having never received HPV vaccine were described according to the socio‐demographic, health‐related, and behavioral characteristics of the study population.

3. RESULTS {#cam43192-sec-0011}
==========

3.1. Characteristics of the study population {#cam43192-sec-0012}
--------------------------------------------

Table [1](#cam43192-tbl-0001){ref-type="table"} describes the sociodemographic, health‐related, and behavioral characteristics of the study sample, stratified by HPV vaccine status. Of the 907 adult respondents included in this study, 198 \[weighted percentage: 21.6% (weighted 95% confidence interval: 18.7‐24.5%)\] reported having ever received (at least one dose of) HPV vaccination, while 530 \[58.5% (55.1‐62.0%)\] reported having never received this vaccine. The remaining 177 respondents \[19.7% (16.8‐22.5%)\] reported not knowing if they have received the HPV vaccine.

###### 

Characteristics of the Study Population according to HPV vaccination status

  Have you ever received the HPV shot, Cervarix, or Gardasil?                                                                                        
  ----------------------------------------------------------------- ----- ------------------ ----- ------------------ ----- ------------------ ----- ------------------
  Age (y)                                                                                                                                            
  18‐28                                                             151   78.9 (73.1‐84.7)   310   63.8 (59.5‐68.1)   131   79.4 (73.5‐85.3)   594   70.2 (67.1‐73.3)
  29‐38                                                             47    21.1 (15.3‐26.9)   220   36.2 (31.9‐40.5)   46    20.6 (14.7‐26.5)   313   29.8 (26.7‐32.9)
  Sex                                                                                                                                                
  Female                                                            165   73.3 (65.6‐80.9)   417   68.5 (63.8‐73.3)   140   65.7 (57.3‐74.2)   724   69.1 (65.4‐72.7)
  Male                                                              33    26.7 (19.1‐34.4)   113   31.5 (26.7‐36.2)   37    34.3 (25.8‐42.7)   183   30.9 (27.3‐34.6)
  Ethnicity/ Race                                                                                                                                    
  Black, non‐Hispanic                                               41    10.1 (6.9‐13.4)    133   12.9 (10.6‐15.3)   39    10.4 (7.0‐13.9)    213   11.8 (10.1‐13.5)
  Hispanic                                                          108   56.4 (48.9‐63.9)   230   46.7 (42.1‐51.3)   99    59.4 (51.4‐67.4)   439   51.4 (47.9‐54.9)
  Others                                                            11    6.4 (2.6‐10.3)     45    8.8 (6.3‐11.4)     11    6.2 (2.5‐10.0)     67    7.8 (5.9‐9.7)
  White, non‐Hispanic                                               38    27.0 (19.7‐34.3)   122   31.5 (27.0‐36.1)   28    23.9 (16.2‐31.6)   188   29.0 (25.5‐32.5)
  Born In USA                                                                                                                                        
  No                                                                16    7.4 (3.8‐11.1)     44    7.5 (5.2‐9.7)      22    12.0 (7.0‐17.0)    82    8.3 (6.5‐10.2)
  Yes                                                               182   92.6 (88.9‐96.2)   486   92.5 (90.3‐94.8)   155   88.0 (83.0‐93.0)   825   91.7 (89.8‐93.5)
  Education                                                                                                                                          
  No greater than 12 y or completed high school                     52    27.7 (20.9‐34.4)   181   35.1 (30.6‐39.5)   88    51.6 (43.6‐59.7)   322   36.8 (33.3‐40.2)
  Post high school training or some college                         69    34.5 (27.3‐41.7)   191   35.1 (30.7‐39.5)   53    30.3 (22.7‐37.8)   313   33.9 (30.6‐37.3)
  College/Postgraduate                                              77    37.8 (30.5‐45.1)   157   29.9 (25.6‐34.1)   36    18.1 (12.1‐24.0)   271   29.3 (26.1‐32.5)
  Marital status                                                                                                                                     
  Single/Widowed/ Divorced/Separated                                119   61.0 (53.7‐68.3)   294   56.8 (52.2‐61.4)   109   61.8 (53.9‐69.6)   524   58.8 (55.3‐62.3)
  Living as Married/Married                                         76    39.0 (31.7‐46.3)   227   43.2 (38.6‐47.8)   66    38.2 (30.4‐46.1)   369   41.2 (37.7‐44.7)
  Occupation                                                                                                                                         
  Employed                                                          122   59.7 (52.2‐67.1)   299   57.2 (52.7‐61.8)   73    40.4 (32.5‐48.4)   494   54.3 (50.8‐57.9)
  Homemaker/Unemployed/Disabled                                     48    24.0 (17.7‐30.2)   151   28.3 (24.2‐32.4)   69    40.2 (32.2‐48.1)   269   29.7 (26.5‐32.9)
  Student/Retired/Other                                             28    16.3 (10.3‐22.4)   78    14.5 (11.2‐17.8)   35    19.4 (13.1‐25.8)   142   15.9 (13.3‐18.6)
  Income                                                                                                                                             
  ≤\$19 999                                                         46    24.1 (17.5‐30.6)   158   28.7 (24.6‐32.9)   73    40.6 (32.7‐48.5)   278   30.1 (26.9‐33.3)
  \$20 000 to \$49 999                                              70    33.8 (26.8‐40.9)   169   31.3 (27.0‐35.5)   60    34.6 (26.8‐42.4)   299   32.4 (29.1‐35.7)
  \$50 000 to \$74 999                                              36    18.3 (12.5‐24.1)   101   17.9 (14.5‐21.3)   21    11.4 (6.5‐16.2)    159   16.8 (14.2‐19.3)
  ≥\$75 000                                                         46    23.8 (17.3‐30.3)   102   22.1 (18.1‐26.2)   23    13.4 (7.8‐19.0)    171   20.7 (17.7‐23.7)
  Residence                                                                                                                                          
  Rural                                                             59    34.9 (27.5‐42.4)   184   39.8 (35.2‐44.4)   69    43.1 (35.1‐51.2)   313   39.4 (35.9‐43.0)
  Urban                                                             139   65.1 (57.6‐72.5)   346   60.2 (55.6‐64.8)   108   56.9 (48.8‐64.9)   594   60.6 (57.0‐64.1)
  Hormonal contraception[^b^](#cam43192-note-0002){ref-type="fn"}                                                                                    
  No                                                                40    16.2 (11.2‐21.3)   161   25.3 (21.6‐29.0)   50    23.7 (17.5‐29.9)   252   23.1 (20.4‐25.8)
  Yes                                                               125   57.1 (49.4‐64.8)   256   43.2 (38.7‐47.7)   90    42.0 (34.3‐49.7)   471   45.9 (42.4‐49.4)
  Smoking                                                                                                                                            
  Current smokers                                                   43    22.4 (16.1‐28.8)   111   22.7 (18.7‐26.7)   41    25.0 (17.9‐32.1)   195   23.1 (20.0‐26.1)
  Former smokers                                                    16    8.9 (4.6‐13.3)     39    7.3 (5.0‐9.7)      13    9.2 (4.2‐14.2)     68    8.0 (6.1‐10.0)
  Never smokers                                                     139   68.6 (61.6‐75.7)   380   70.0 (65.6‐74.3)   123   65.8 (58.0‐73.6)   643   68.9 (65.5‐72.2)
  Health care coverage                                                                                                                               
  No                                                                58    31.5 (24.4‐38.7)   201   37.3 (32.8‐41.8)   84    47.0 (38.9‐55.1)   343   38.0 (34.5‐41.4)
  Yes                                                               139   68.5 (61.3‐75.6)   329   62.7 (58.2‐67.2)   93    53.0 (44.9‐61.1)   561   62.0 (58.6‐65.5)
  Hepatitis B Virus vaccination                                                                                                                      
  No                                                                53    26.3 (19.6‐32.9)   350   66.9 (62.6‐71.3)   77    43.5 (35.4‐51.5)   480   53.4 (49.9‐56.9)
  Yes                                                               145   73.7 (67.1‐80.4)   180   33.1 (28.7‐37.4)   100   56.5 (48.5‐64.6)   425   46.4 (42.9‐49.9)
  Family History of any cancer                                                                                                                       
  No                                                                48    22.2 (16.0‐28.3)   206   36.5 (32.1‐41.0)   53    28.1 (21.1‐35.1)   307   31.8 (28.5‐35.0)
  Not sure                                                          19    11.0 (5.8‐16.2)    57    12.7 (9.4‐16.0)    29    17.3 (11.0‐23.5)   105   13.2 (10.7‐15.8)
  Yes                                                               131   66.9 (59.7‐74.0)   266   50.8 (46.1‐55.4)   95    54.6 (46.6‐62.6)   492   55.0 (51.5‐58.5)

2 participants did not provide information about their vaccination status.

Male participants did not respond to the question about hormonal contraception use.

John Wiley & Sons, Ltd

HPV unvaccinated vs vaccinated respondents were more frequently: aged between 29 and 38 years \[36.2% (31.9‐40.5) vs 21.1% (15.3‐26.9)\]; males \[31.5% (26.7‐36.2) vs \[26.7% (19.1‐34.4)\], and NHWs \[31.5% (27.0‐36.1) vs 27.0% (19.7‐34.3)\]. HPV unvaccinated respondents were also more likely to: have a level of education not greater than 12 years \[35.1% (30.6‐39.5) vs 27.7% (20.9‐34.4)\]; and to reside in rural areas \[(39.8% (35.2‐44.4) vs 34.9% (27.5‐42.4)\], compared with their vaccinated counterparts. (Table [1](#cam43192-tbl-0001){ref-type="table"}).

HPV unvaccinated respondents were less likely to: use hormonal contraception \[43.2% (38.7‐47.7) vs 57.1% (49.4‐64.8)\]; have health insurance \[62.7% (58.2‐67.2) vs 68.5% (61.3‐75.6)\]; be vaccinated against HBV \[33.1% (28.7‐37.4) vs 73.7% (67.1‐80.4)\]; and have a family history of cancer \[50.8% (46.1‐55.4) vs 66.9% (59.7‐74.0)\], compared with HPV vaccinated respondents. (Table [1](#cam43192-tbl-0001){ref-type="table"}).

3.2. Reasons for having not received HPV vaccination {#cam43192-sec-0013}
----------------------------------------------------

The main reasons for not getting the HPV vaccine differed by certain demographics including sex, ethnicity/race, and education and are reported in Figures [1](#cam43192-fig-0001){ref-type="fig"}, [2](#cam43192-fig-0002){ref-type="fig"}, [3](#cam43192-fig-0003){ref-type="fig"}, [4](#cam43192-fig-0004){ref-type="fig"} and the Table [S1](#cam43192-sup-0001){ref-type="supplementary-material"}. Overall, the most frequently reported reasons were: "did not know about the vaccine" \[18.5% (14.9‐22.1)\], "provider did not recommend" \[14.2% (10.9‐17.4)\], "vaccine not needed or necessary" \[13.8% (10.5‐17.0)\], and "not sexually active" \[13.7% (10.5‐16.9)\] (Figure [1](#cam43192-fig-0001){ref-type="fig"}). Among women, the most common reason reported was 'did not know about the vaccine' \[18.6% (14.7‐22.6)\], while among men, it was "not sexually active" \[20.3% (12.7‐27.9)\] (Figure [2](#cam43192-fig-0002){ref-type="fig"}). Among NHWs, the most common reason was "vaccine not needed or necessary" \[19.8% (12.2‐27.5)\], while it was "did not know about the vaccine" among Hispanics \[20.1% (14.7‐25.4)\], and "not sexually active" among NHBs \[24.7% (16.8‐32.6)\] (Figure [3](#cam43192-fig-0003){ref-type="fig"}). Among women with post‐graduate education, the main reason reported was "provider did not recommend" \[18.0% (11.3‐24.7)\]; while in women with not greater than high school education, the main reason was "did not know about the vaccine" \[21.8% (15.3‐28.4)\] (Figure [4](#cam43192-fig-0004){ref-type="fig"}).

![Main Reasons for not getting the HPV vaccine among vaccine‐eligible adults, overall](CAM4-9-5281-g001){#cam43192-fig-0001}

![Main Reasons for not getting the HPV vaccine among vaccine‐eligible adults, by sex](CAM4-9-5281-g002){#cam43192-fig-0002}

![Reasons for not getting the HPV vaccine among vaccine‐eligible adults, by race/ethnicity](CAM4-9-5281-g003){#cam43192-fig-0003}

![Reasons for not getting the HPV vaccine among vaccine‐eligible adults, by education level](CAM4-9-5281-g004){#cam43192-fig-0004}

Some of the key least commonly reported reasons for not getting HPV vaccine included: "safety concerns" (7.2% (4.8‐9.5)); "uninsured or insurance doesn\'t fully cover shots" (3.4% (1.7‐5.1)); "concerns about increasing sexual activity if receive the vaccine" \[0.2% (0.0‐0.5)\]; and "difficulty making or getting to appointments, or transportation issues" (0.2% (0.0‐0.4)) (Figure [1](#cam43192-fig-0001){ref-type="fig"}).

Reasons for not having received HPV vaccination described according to respondents' characteristics age, origin of birth, marital status, occupational status, income, residency, use of hormonal contraception, smoking status, availability of health care, vaccination status for hepatitis B, and family history of cancer are reported in the Table [S1](#cam43192-sup-0001){ref-type="supplementary-material"}.

4. DISCUSSION {#cam43192-sec-0014}
=============

In this representative sample of adult Texas residents eligible for HPV vaccination, differences in socio‐demographic, health‐related, and behavioral characteristics were assessed between those who reported having ever received the HPV vaccine, and those who had never been vaccinated for HPV. Among eligible respondents who reported having not received HPV vaccination, we examined the reasons why they did not get the vaccine. To the best of our knowledge, this is the first study to assess individual\'s reasons for not receiving HPV vaccine in the Texas adult population, a state with an alarmingly low HPV vaccine uptake.

Texas has experienced a 20‐fold increase in nonmedical exemptions of vaccination for students since 2003 when exemptions for religious and personal beliefs were enacted.[^15^](#cam43192-bib-0015){ref-type="ref"}, [^16^](#cam43192-bib-0016){ref-type="ref"} It is also one of the US States with the lowest HPV vaccination rates.[^18^](#cam43192-bib-0018){ref-type="ref"} The growing number of unvaccinated children arriving at Texas schools makes this state increasingly vulnerable to vaccine preventable outbreaks, according to a recent computer simulation.[^17^](#cam43192-bib-0017){ref-type="ref"} To help improve HPV vaccination rates, the Texas Medical Association recently joined with more than 40 other organizations to announce a renewed statewide immunization campaign to prevent HPV‐related cancers.[^24^](#cam43192-bib-0024){ref-type="ref"} Despite these efforts, the impact that the rising number of anti‐vaccine movements in the State have had on HPV vaccination coverage remains unknown. In order to examine the various reasons expressed by potential adult beneficiaries for the low HPV vaccination uptake, we administered this state‐wide survey. Excluding participants who did not know their HPV vaccination status from our study population, 28.3% of women and 23.8% of men reported having ever received HPV vaccination. Based on the NHIS data, HPV vaccination rates (at least one dose, ever) in 2016 were 48.5% among women aged 19 to 26 years, and 21.2% among men aged 19‐21 years.[^5^](#cam43192-bib-0005){ref-type="ref"} Our study finding suggests that the lower HPV vaccination uptake among eligible adults in Texas, as compared to national rates, is driven by relatively lower HPV vaccination rate among adult vaccine‐eligible women in Texas. Further studies are needed to understand barriers to HPV vaccination among women in Texas, and the reasons why they are less likely to be vaccinated for HPV than the average adult woman in the US.

HPV vaccination is routinely administered between 11 and 12 years with parental consent (2). However, catch‐up immunization is recommended for both men and women through early adulthood,[^2^](#cam43192-bib-0002){ref-type="ref"} when individuals can independently make an informed choice about their health, including the decision about HPV vaccination. Thus, beyond parents' perspectives, understanding individuals' reasons for not receiving HPV vaccine is critical to improving vaccine uptake among eligible adults. In line with the recent FDA approval of HPV vaccine until age 45,[^11^](#cam43192-bib-0011){ref-type="ref"} the ACIP has recommended its use among US adults aged 27 to 45 years as part of shared clinical decision‐making.[^13^](#cam43192-bib-0013){ref-type="ref"} In this context, it is essential to examine the reasons for non‐initiation of HPV vaccination in the adult eligible population.

In our study sample, lack of knowledge about HPV vaccine, lack of provider\'s recommendation, and perceived lack of necessity, were the most commonly reported reasons for not getting the vaccine. Interestingly, these reasons varied by certain demographics. Among women, the main reason for not getting the HPV vaccine was "did not know about the vaccine", while among men, it was "not sexually active." In a study assessing US parents' reasons for lack of HPV vaccine initiation in their children, "safety concerns" was most frequently reported by parents of eligible girls vs "lack of necessity" by parents of eligible boys.[^25^](#cam43192-bib-0025){ref-type="ref"} It is well known that children\'s values and practices are generally influenced by their parents' beliefs and attitudes.[^26^](#cam43192-bib-0026){ref-type="ref"}, [^27^](#cam43192-bib-0027){ref-type="ref"} Our findings, however, suggest that when they become adults, children may not necessarily give the same reasons as their parents for not receiving HPV vaccine. This highlights the need to develop adapted educational interventions to improve HPV vaccine uptake among eligible adults. The finding that sexual inactivity is a major reason for nonreceipt of HPV vaccine among men, may reflect their poorer understanding of the need to vaccinate before sexual debut. This is consistent with prior literature demonstrating less frequent, weaker, and less timely HPV vaccine recommendations for men compared to women, despite evidence that provider recommendation may have an even stronger impact on men\'s vaccine initiation.[^28^](#cam43192-bib-0028){ref-type="ref"} Because providers who feel that they must discuss sexuality prior to recommending the vaccine tend to deliver lower quality, less frequent recommendations,[^28^](#cam43192-bib-0028){ref-type="ref"} targeted interventions are needed to improve the impact of messages that providers deliver to patients. Only 0.2% of respondents (regardless of sex) reported concerns that the vaccine would increase their sexual activity. Therefore, providers' concerns about discussing sexual activity is not relevant for vaccine‐eligible adult individuals unlike for parents of vaccine‐eligible adolescents,[^29^](#cam43192-bib-0029){ref-type="ref"} and thus, should not obstruct delivery of strong recommendations, especially among women.

Although the HPV vaccine was FDA approved to prevent cancer over a decade ago, eligible adults still report a lack of knowledge and understanding of its necessity. However, safety concerns, lack of insurance, transportation issues as well as some other concerns were less common in our study sample, suggesting that reasons commonly highlighted in mainstream media, such as anti‐vaccination beliefs including religious objections are not the prime factors underlying individuals' perception of HPV vaccination in Texas.[^30^](#cam43192-bib-0030){ref-type="ref"}

5. STRENGTHS AND LIMITATIONS {#cam43192-sec-0015}
============================

Strengths of the study include its large sample size and the representativeness of the adult Texas population. The study is somewhat limited, however, in its ability to detect simultaneous reasons individuals may hold, as the question was framed to assess the "main" reason for not getting the vaccine. Because information about whether or how often eligible individuals visited a healthcare provider was not available, we could not distinguish between respondents with missed clinical opportunities for HPV vaccine recommendation, and those unexposed to provider recommendations. While the self‐report of the vaccine status by study participants could yield a certain level of "misclassification" bias, substantial agreement between electronic medical reports of the vaccine status and self‐reported data were noted for HPV vaccination.[^31^](#cam43192-bib-0031){ref-type="ref"}

6. CONCLUSION {#cam43192-sec-0016}
=============

In this study, individual reasons for not receiving the HPV vaccine were assessed among eligible adults. A substantial proportion of age‐eligible adults in Texas reported lack of knowledge or lack of provider recommendation as the main reasons for not receiving HPV vaccine. Rather than emphasizing on safety or sexual activity, educational interventions should focus on the necessity and awareness of HPV vaccination. Providers' recommendation for HPV vaccine should be reinforced, and further adapted to older age groups.
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